Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Myocardial Injury for COVID-19 Even in Young Patients with Mild Symptoms

Most young COVID-19 patients not requiring hospitalization showed abnormal cardiac magnetic resonance imaging (CMR) beyond two months after diagnosis.

Injuria miocárdica por COVID-19 incluso en jóvenes y con síntomas leves

Myocardial injury had been found in more serious cases, but not in a healthy population recovered at home.

The increasing evidence of the virus’ capacity to directly affect the heart across the whole population and disease severity spectrum turns our previous article published on March 3 obsolete. In only 5 months, we went from denying myocarditis to saying it is frequent, and that it might even be the norm.

78% of patients in a center in Germany showed abnormal CMR findings 2 to 3 months after testing positive for COVID 19 and despite the fact that 67% of these patients never required hospitalization.


Read also: Infarction, Stroke and Aortic Emergency Syndromes in the Shadow of the Pandemic.


Conventional CMR sequences were used to assess cardiac function, volume, myocardial mass and scars in addition to myocardial mapping in T1 and T2.

The study included 100 patients recovering from the infection (mean age 49) who received high-sensitivity troponin T and CMR testing. A few patients in the group presented traditional risk factors, but only one third was hospitalized and only 2 required mechanical ventilation.

In most patients (78%) troponin was detected at CMR time, even though it had been between 64 and 92 days after diagnosis.


Read also: Temporary Emergency Guidelines for Infarction During the Pandemic.


The publication of this study in JAMA Cardiology has raised many questions that remain unanswered. What should we do with these findings and how long will they persist? Is it necessary to take cardio-protection measures of some kind, with anti-inflammatory or cardiac failure medication?

The answers will come from centers that have already fought the first wave while the rest of us weather the storm.

Original Title: Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19).

Reference: Puntmann VO et al. JAMA Cardiol. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...